Sort
261,768 grants matching “gene therapy”
Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor
$999,998Frederick Wayne Holtsberg · Kinarx, Llc · R44 · FY2021 · CA
Rescuing the Fragile X Syndrome by Resetting Translational Homeostasis
$999,998Joel D Richter · Univ Of Massachusetts Med Sch Worcester · U54 · FY2019 · HD
Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD
$999,998Dominick Auci · Therapyx, Inc. · R44 · FY2019 · AI
Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy
$999,998Hunter Nicole Bomba · Cancer Targeted Technology, Llc · R44 · FY2022 · CA
Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD
$999,998Dominick Auci · Therapyx, Inc. · R44 · FY2017 · AI
SBIR Phase II: A Bioprocessing System to Isolate and Purify Therapeutic Antibodies Directly from Cell Culture.
$999,998Sunil Mehta · Athem L.L.C. · · FY2024 · TIP
Novel, Non-hormonal Therapeutic for Endometriosis
$999,998Tanya Christineh Petrossian · Endomet Biosciences, Inc · R44 · FY2024 · HD
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER
$999,998Darren Orton · Stemsynergy Therapeutics, Inc. · R44 · FY2018 · CA
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
$999,997Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2024 · AI
Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia
$999,997Gary G. Altman · Cambium Oncology Llc · R44 · FY2025 · CA
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
$999,997Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2025 · AI
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia
$999,997Atul Varadhachary · Fannin Partners, Llc · R44 · FY2025 · CA
Novel, Non-hormonal Therapeutic for Endometriosis
$999,997Tanya Christineh Petrossian · Endomet Biosciences, Inc · R44 · FY2023 · HD
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia
$999,997Atul Varadhachary · Fannin Partners, Llc · R44 · FY2022 · CA
Preclinical evaluation of a novel small molecule STAT inhibitor
$999,993Robert Sons · Fannin Partners, Llc · R44 · FY2018 · AI
Optimizing SIV reservoir depletion by Tendel bsAb-98
$999,991Ellen Elizabeth Sparger · Tendel Therapies Inc. · R44 · FY2025 · AI
Targeting lipid rafts for treatment of asthma
$999,991Yakov Kogan · Raft Pharmaceuticals, Llc · R44 · FY2023 · AI
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
$999,989Neil A Fanger · Virtici, Llc · R44 · FY2025 · HL
Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs
$999,986Michelle M. Butler · Microbiotix, Inc · R44 · FY2019 · AI
There Will Be Blood: Stem Cell Niche Driven Derivation of HSC from ES Cells
$999,983Naoki Nakayama · University Of Texas Hlth Sci Ctr Houston · RC1 · FY2010 · HL
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER
$999,981Darren Orton · Stemsynergy Therapeutics, Inc. · R44 · FY2019 · CA
Screening for rAAV transduction enhancers
$999,976Terry L Bowlin · Microbiotix, Inc · R44 · FY2021 · AI
Humanized monoclonal antibodies to treat mucormycosis
$999,975Gary Lazar · Vitalex Biosciences, Llc · R44 · FY2024 · AI
GENHAT-GENETICS OF HYPERTENSION ASSOCIATED TREATMENTS
$999,971University Of Alabama At Birmingham · R01 · FY2003 · HL
Novel biologic to treat chemotherapy-induced neuropathic pain
$999,967Yakov Kogan · Raft Pharmaceuticals, Llc · R44 · FY2022 · CA